FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Merck | CDC | Zostavax

CDC backs wide use of Merck's Zostavax

Tools

TODAY'S SPOTLIGHT... CDC backs wide use of Merck's Zostavax
The Centers for Disease Control and Prevention is giving a boost to Merck's Zostavax vaccine. The public health agency is recommending that all adults 60 years and older should get the herpes zoster shot to prevent shingles, a painful and sometimes long-lasting disease. Complications of shingles, such a pneumonia and blindness, are more common among older folks. The CDC's advice comes after a long peer-review process, and its official stamp could prompt more doctors to give the vaccine--and, importantly, more private insurance companies to cover it. Release | Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about Merck   CDC   Zostavax